Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16618672 | 0.99 | HTR6 (0.38) | HTR6MAPTMAPK1L3MBTL1IDE | |
| SCHEMBL16626671 | 0.95 | HTR6 (0.41) | HTR6IDE | |
| Hydrochloric Acid SCHEMBL16618624 | 0.94 | HTR6 (0.41) | HTR6IDE | |
| SCHEMBL17971519 | 0.93 | HTR6 (0.42) | HTR6MAPTIDECHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL16619115 | 0.92 | HTR6 (0.41) | HTR6MAPTIDEHTR2ACHRNB4 | |
| SCHEMBL16626399 | 0.92 | HTR6 (0.40) | HTR6MAPTIDESCN9ACHRNB4 | |
| Hydrochloric Acid SCHEMBL16619176 | 0.91 | HTR6 (0.39) | HTR6MAPTIDESCN9ACHRNB4 | |
| SCHEMBL16626670 | 0.90 | HTR6 (0.45) | HTR6IDECHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL16619107 | 0.89 | HTR6 (0.44) | HTR6IDEHTR2ACHRNB4CHRNA3 | |
| SCHEMBL16626438 | 0.89 | HTR6 (0.39) | HTR6IDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | claimed |
| EP-3052484-B1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAE WOONG PHARMA (KR) | 2018-03-21 | — | — | EP | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676714-B2 | Sulfonylindole derivatives and method for preparing the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| WO-2015050412-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221946-A1 | SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME | GIPR, PGC, SI | HTR6 166/4885MAPT 4683/4885MAPK1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.